In brief
A modelling study published in Nature Medicine projects a 20.2 % rise in new cervical cancer cases and a 39.3 % jump in deaths by 2050, reaching 1.08 million cases and 522,000 deaths annually. Sub‑Saharan Africa is poised for the largest surge, with cases and deaths predicted to nearly double. The research underscores continued disparities in vaccine and screening access, highlighting gaps that could widen existing inequities. The study’s predictions leave room for uncertainty around vaccination rollout, screening coverage and health‑system responses, factors that could influence the accuracy of the forecasts.
A recent modelling study published in Nature Medicine projects that the global burden of cervical cancer will rise sharply over the next decades. The authors predict a 20.2 % increase in annual new cases and a 39.3 % increase in deaths by 2050, taking those figures to 1.08 million cases and 522,000 deaths per year, up from the 887,000 new cases and 369,000 deaths recorded worldwide in 2023.
The projections were derived from an analysis of cervical cancer incidence, mortality and health loss data collected across 204 countries and territories from 1990 to 2023. Researchers from Australia and several international institutions fed the data into a model that extrapolated trends forward to 2050. The study noted that none of the seven global regions examined is likely to meet the World Health Organization’s elimination target of fewer than four cases per 100,000 women before 2050 if current patterns persist.
Sub‑Saharan Africa stands out as the region that will experience the steepest rise. The study estimates that annual cases will increase by 88.7 % and deaths by 95.4 %, reaching an estimated 206,000 deaths by 2050—a figure that almost doubles the 2023 death count for the region. In 2023, the age‑standardized incidence rate of cervical cancer was over four times higher in low‑income countries than in high‑income countries, while the mortality rate was more than seven times higher, underscoring stark disparities in health‑system capacity and access to prevention.
Because cervical cancer is largely preventable through vaccination against human papillomavirus (HPV) and regular screening, the authors called for expanded access to both measures. They added that current access to HPV vaccination, screening and treatment varies widely around the world, a factor that could either exacerbate or mitigate the predicted increases depending on how health‑investment priorities shift in the coming years.
While the study offers a comprehensive look at global trends, the authors highlighted that the predictions are contingent on current vaccination and screening uptake remaining unchanged. The modelling also assumes that no major breakthroughs in treatment or public‑health policy will occur that could alter the trajectory of incidence or mortality.
Uncertainties remain regarding how quickly vaccine coverage can be expanded in low‑income settings, how screening programs can be scaled, and how health‑system resources will be distributed. The study itself does not provide a range of possible futures but rather a single forecast based on existing data and trend extrapolation. These uncertainties point to the need for continued investment in prevention and early‑detection efforts, as well as further research to refine future predictions. The authors’ call to improve access to HPV vaccination, screening and treatment remains central to any strategy aimed at preventing the predicted rise in cervical cancer cases and deaths.
